John D Parker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8114248/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Influence of Obstructive Sleep Apnea on Mortality in Patients With Heart Failure. Journal of the American College of Cardiology, 2007, 49, 1625-1631.	2.8	546
2	Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet, The, 2004, 364, 849-857.	13.7	468
3	Nitrate Therapy for Stable Angina Pectoris. New England Journal of Medicine, 1998, 338, 520-531.	27.0	357
4	Sleepiness and Sleep in Patients With Both Systolic Heart Failure and Obstructive Sleep Apnea. Archives of Internal Medicine, 2006, 166, 1716.	3.8	335
5	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 2009.	7.4	330
6	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation, 2006, 114, 1202-1213.	1.6	320
7	Prevalence and Physiological Predictors of Sleep Apnea in Patients With Heart Failure and Systolic Dysfunction. Journal of Cardiac Failure, 2009, 15, 279-285.	1.7	217
8	B-Type Natriuretic Peptide in Pregnant Women With Heart Disease. Journal of the American College of Cardiology, 2010, 56, 1247-1253.	2.8	171
9	Nonselective Versus Selective Î ² -Adrenergic Receptor Blockade in Congestive Heart Failure. Circulation, 2001, 104, 2194-2199.	1.6	166
10	Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance. Circulation, 2001, 104, 1119-1123.	1.6	165
11	Conduit Artery Constriction Mediated by Low Flow. Journal of the American College of Cardiology, 2008, 51, 1953-1958.	2.8	143
12	Nitrate Tolerance. Circulation, 2002, 106, 2510-2513.	1.6	141
13	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Canadian Journal of Cardiology, 2007, 23, 21-45.	1.7	131
14	Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. Journal of the American College of Cardiology, 2001, 38, 854-859.	2.8	127
15	Sildenafil Prevents Endothelial Dysfunction Induced by Ischemia and Reperfusion via Opening of Adenosine Triphosphate–Sensitive Potassium Channels. Circulation, 2005, 111, 742-746.	1.6	123
16	Use of skin conductance changes during mental stress testing as an index of autonomic arousal in cardiovascular research. American Heart Journal, 1994, 128, 1170-1177.	2.7	116
17	Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans. Journal of the American College of Cardiology, 2007, 49, 1289-1295.	2.8	116
18	Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. Journal of the American College of Cardiology, 1996, 28, 155-161.	2.8	111

#	Article	IF	CITATIONS
19	Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. Journal of the American College of Cardiology, 2001, 38, 1096-1101.	2.8	107
20	Acute Effects of β ₁ -Selective and Nonselective β-Adrenergic Receptor Blockade on Cardiac Sympathetic Activity in Congestive Heart Failure. Circulation, 1996, 94, 353-358.	1.6	104
21	Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. Journal of the American College of Cardiology, 1998, 32, 1969-1974.	2.8	100
22	Reducing Cardiac Filling Pressure Lowers Norepinephrine Spillover in Patients With Chronic Heart Failure. Circulation, 2000, 101, 2053-2059.	1.6	100
23	Long-term endothelial dysfunction after coronary artery stenting. Journal of the American College of Cardiology, 1999, 34, 1675-1679.	2.8	98
24	The Puzzle of Nitrate Tolerance. Circulation, 2002, 106, 2404-2408.	1.6	94
25	"Dose-dependent―Impact of Recurrent Cardiac Events on Mortality in Patients with Heart Failure. American Journal of Medicine, 2009, 122, 162.e1-162.e9.	1.5	89
26	Increased ventricular repolarization heterogeneity in patients with ventricular arrhythmia vulnerability and cardiomyopathy: a human in vivo study. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H79-H86.	3.2	83
27	Endothelial function assessment: flow-mediated dilation and constriction provide different and complementary information on the presence of coronary artery disease. European Heart Journal, 2012, 33, 363-371.	2.2	81
28	Parasympathetic Control of Cardiac Sympathetic Activity. Circulation, 1999, 100, 274-279.	1.6	80
29	Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1522.	7.4	79
30	Biventricular Pacemaker Upgrade in Previously Paced Heart Failure Patients—Improvements in Ventricular Dyssynchrony. Journal of Cardiac Failure, 2006, 12, 199-204.	1.7	76
31	Relationship of Systolic BP to Obstructive Sleep Apnea in Patients With Heart Failure. Chest, 2003, 123, 1536-1543.	0.8	72
32	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 2005, 150, 46-53.	2.7	67
33	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. Journal of Cardiac Failure, 2015, 21, 179-188.	1.7	65
34	Relation of Periodic Leg Movements During Sleep and Mortality in Patients With Systolic Heart Failure. American Journal of Cardiology, 2011, 107, 447-451.	1.6	62
35	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. American Journal of Cardiology, 2005, 95, 36-42.	1.6	61
36	Inotropic and Sympathetic Responses to the Intracoronary Infusion of a \hat{I}^2 2 -Receptor Agonist. Circulation, 1999, 99, 2402-2407.	1.6	58

#	Article	IF	CITATIONS
37	Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. American Journal of Cardiology, 2003, 91, 1392-1394.	1.6	57
38	Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. British Journal of Clinical Pharmacology, 2007, 64, 145-150.	2.4	57
39	The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. Journal of the American College of Cardiology, 2002, 39, 1199-1203.	2.8	56
40	Flow-mediated constriction: further insight into a new measure of vascular function. European Heart Journal, 2011, 32, 784-787.	2.2	56
41	Nitrate-Induced Toxicity and Preconditioning. Journal of the American College of Cardiology, 2008, 52, 251-254.	2.8	55
42	Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. Journal of the American College of Cardiology, 1993, 21, 1445-1453.	2.8	53
43	Avoidance of the left lateral decubitus position during sleep in patients with heart failure: relationship to cardiac size and function. Journal of the American College of Cardiology, 2003, 41, 227-230.	2.8	53
44	Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia. Hypertension, 2017, 69, 180-188.	2.7	53
45	Left Ventricular Structural Adaptations to Obstructive Sleep Apnea in Dilated Cardiomyopathy. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1170-1175.	5.6	52
46	Lack of evidence for peripheral alpha1- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. Journal of the American College of Cardiology, 2001, 38, 1463-1469.	2.8	51
47	Left Ventricular Strain Patterns in Dilated Cardiomyopathy Predict Response to Cardiac Resynchronization Therapy: Timing Is Not Everything. Journal of the American Society of Echocardiography, 2009, 22, 242-250.	2.8	50
48	Cardiac sympathetic activation in patients with pulmonary arterial hypertension. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R1153-R1157.	1.8	50
49	Impact of Autonomic Regulation Therapy in Patients with Heart Failure. Circulation: Heart Failure, 2019, 12, e005879.	3.9	50
50	Pentaerythrityl Tetranitrate and Nitroglycerin, but not Isosorbide Mononitrate, Prevent Endothelial Dysfunction Induced by Ischemia and Reperfusion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1955-1959.	2.4	49
51	Nitrate tolerance, oxidative stress, and mitochondrial function: another worrisome chapter on the effects of organic nitrates. Journal of Clinical Investigation, 2004, 113, 352-354.	8.2	49
52	Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. Journal of the American College of Cardiology, 2001, 37, 505-509.	2.8	48
53	Cardiac resynchronisation therapy: an option for inotrope-supported patients with end-stage heart failure?. European Journal of Heart Failure, 2005, 7, 215-217.	7.1	46
54	Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. Journal of the American College of Cardiology, 1992, 20, 616-622.	2.8	45

#	Article	IF	CITATIONS
55	Effects of nitroglycerin treatment on baroreflex sensitivity andshort-term heart rate variability in humans. Journal of the American College of Cardiology, 2002, 40, 2000-2005.	2.8	44
56	Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2–Dependent Mechanism. Journal of the American College of Cardiology, 2010, 55, 1002-1006.	2.8	44
57	Cardiac Sympathetic Responses to Acute Vasodilation. Circulation, 1996, 94, 3161-3167.	1.6	44
58	Selective versus nonselective βâ€adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. European Journal of Heart Failure, 2005, 7, 618-623.	7.1	43
59	Ontario Multidetector Computed Tomographic Coronary Angiography Study. Archives of Internal Medicine, 2011, 171, 1021-9.	3.8	41
60	Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. Journal of the American College of Cardiology, 1999, 33, 186-191.	2.8	40
61	Cardiac-specific sympathetic activation in men and women with and without heart failure. Heart, 2011, 97, 382-387.	2.9	38
62	Intermittent Transdermal Nitroglycerin Therapy. Circulation, 1995, 91, 973-978.	1.6	38
63	Serial assessment of left ventricular function and mass after orthotopic heart transplantation: A 4-year longitudinal study. Journal of the American College of Cardiology, 1992, 19, 60-66.	2.8	36
64	The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. Journal of the American College of Cardiology, 2002, 39, 1269-1274.	2.8	36
65	Contrast nephropathy post cardiac resynchronization therapy: An under-recognized complication with important morbidity. European Journal of Heart Failure, 2005, 7, 899-903.	7.1	36
66	Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. Sexual Medicine Reviews, 2018, 6, 583-594.	2.9	35
67	Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H340-H345.	3.2	33
68	Should Maternal Hemodynamics Guide Antihypertensive Therapy in Preeclampsia?. Hypertension, 2018, 71, 550-556.	2.7	33
69	Coadministration of Atorvastatin Prevents Nitroglycerin-Induced Endothelial Dysfunction and Nitrate Tolerance in Healthy Humans. Journal of the American College of Cardiology, 2011, 57, 93-98.	2.8	32
70	Effects of Diuretic Therapy on the Development of Tolerance to Nitroglycerin and Exercise Capacity in Patients With Chronic Stable Angina. Circulation, 1996, 93, 691-696.	1.6	31
71	Neurohormonal activation during nitrate therapy: A possible mechanism for tolerance. American Journal of Cardiology, 1992, 70, B93-B97.	1.6	29
72	Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H939-H945.	3.2	29

#	Article	IF	CITATIONS
73	Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover. European Journal of Heart Failure, 2005, 7, 878-881.	7.1	28
74	Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial*. Critical Care Medicine, 2007, 35, 1863-1868.	0.9	28
75	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <scp>VERITAS</scp> study. European Journal of Heart Failure, 2014, 16, 1362-1371.	7.1	28
76	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (<scp>VERITAS</scp>). European Journal of Heart Failure, 2017, 19, 739-747.	7.1	28
77	Phenotypes of Pregnant Women Who Subsequently Develop Hypertension in Pregnancy. Journal of the American Heart Association, 2018, 7, .	3.7	28
78	Functional Significance of Presynaptic α-Adrenergic Receptors in Failing and Nonfailing Human Left Ventricle. Circulation, 1995, 92, 1793-1800.	1.6	28
79	The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. European Journal of Heart Failure, 2006, 8, 864-868.	7.1	27
80	Daily Ischemic Preconditioning Provides Sustained Protection From Ischemia–Reperfusion Induced Endothelial Dysfunction: A Human Study. Journal of the American Heart Association, 2013, 2, e000075.	3.7	27
81	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. Journal of Cardiac Failure, 2016, 22, 815-822.	1.7	27
82	Impaired Baroreceptor Control of Renal Sympathetic Activity in Human Chronic Heart Failure. Circulation, 2004, 109, 2862-2865.	1.6	26
83	Nitroglycerin Attenuates Human Endothelial Progenitor Cell Differentiation, Function, and Survival. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 117-123.	2.5	26
84	Effects of Renal Artery Denervation on Ventricular Arrhythmias in a Postinfarct Model. Circulation: Cardiovascular Interventions, 2017, 10, e004172.	3.9	26
85	Peripheral hemorheological and vascular correlates of coronary blood flow. Clinical Hemorheology and Microcirculation, 2011, 49, 261-269.	1.7	25
86	Low molecular weight heparin for the prevention of severe preeclampsia: where next?. British Journal of Clinical Pharmacology, 2018, 84, 673-678.	2.4	24
87	Electrical and hemodynamic correlates of the maximal rate of pressure increase in the human left ventricle. Journal of Cardiac Failure, 1999, 5, 8-16.	1.7	23
88	Fibrinogen synthesis is increased in cachectic patients with chronic heart failure. International Journal of Cardiology, 2008, 129, 363-367.	1.7	23
89	Biochemical, Hemodynamic, and Vascular Evidence Concerning the Free Radical Hypothesis of Nitrate Tolerance. Journal of Cardiovascular Pharmacology, 1999, 33, 685-690.	1.9	23
90	The Effects of Dobutamine on Renal Sympathetic Activity in Human Heart Failure. Journal of Cardiovascular Pharmacology, 2008, 51, 434-436.	1.9	22

#	Article	IF	CITATIONS
91	ARCTIC: Assessment of haemodynamic Response in patients with Congestive heart failure to Telmisartan: A multicentre dose-ranging study In Canada. American Heart Journal, 1999, 138, 843-848.	2.7	21
92	The Angiotensin II-Receptor Antagonist Losartan Does Not Prevent Hemodynamic or Vascular Tolerance to Nitroglycerin. Journal of Cardiovascular Pharmacology, 1999, 34, 645-650.	1.9	21
93	Effects of percutaneous mitral valvuloplasty on left ventricular mass and volume. American Journal of Cardiology, 1991, 68, 940-944.	1.6	20
94	Cardiac Resynchronization Therapy: Retiming the Failing Right Ventricle. Journal of Cardiovascular Electrophysiology, 2005, 16, 439-443.	1.7	20
95	Mechanisms and Clinical Significance of Endothelial Dysfunction in High-Risk Pregnancies. Canadian Journal of Cardiology, 2018, 34, 371-380.	1.7	20
96	Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322.	7.1	20
97	Effect of Folic Acid on Nitrate Tolerance in Healthy Volunteers: Differences between Arterial and Venous Circulation. Journal of Cardiovascular Pharmacology, 2003, 41, 185-190.	1.9	19
98	Nitroglycerine causes mitochondrial reactive oxygen species production: In vitro mechanistic insights. Canadian Journal of Cardiology, 2007, 23, 990-992.	1.7	19
99	The mechanism of nitrate-induced preconditioning. Clinical Hemorheology and Microcirculation, 2008, 39, 191-196.	1.7	19
100	Current Theories on the Prevention of Severe Preeclampsia With Low-Molecular Weight Heparin. Hypertension, 2015, 66, 1098-1103.	2.7	19
101	A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 375-386.	2.0	19
102	Sympathetic Responses to Atrial Natriuretic Peptide in Patients with Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 2000, 35, 129-135.	1.9	19
103	Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: a human in vivo study. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H888-H894.	3.2	18
104	Effects of estradiol on measurements of conduit artery endothelial function after ischemia and reperfusion in premenopausal women. Canadian Journal of Physiology and Pharmacology, 2016, 94, 1304-1308.	1.4	18
105	Continuous Therapy with Nitroglycerin Impairs Endothelium-Dependent Vasodilation but Does Not Cause Tolerance in Conductance Arteries. Journal of Cardiovascular Pharmacology, 2004, 44, 601-606.	1.9	17
106	Haemodynamic and structural correlates of the first and second heart sounds in pulmonary arterial hypertension: an acoustic cardiography cohort study. BMJ Open, 2013, 3, e002660.	1.9	17
107	Tolerance to the Organic Nitrates. Circulation, 2001, 104, 2263-2265.	1.6	16
108	Peak oxygen uptake is not determined by cardiac noradrenaline spillover in heart failure. European Heart Journal, 2002, 23, 800-805.	2.2	16

#	Article	IF	CITATIONS
109	Postconditioning fails to prevent radial artery endothelial dysfunction induced by ischemia and reperfusion: evidence from a human in vivo study. Canadian Journal of Physiology and Pharmacology, 2006, 84, 611-615.	1.4	16
110	Stable Angina Pectoris: The Medical Management of Symptomatic Myocardial Ischemia. Canadian Journal of Cardiology, 2012, 28, S70-S80.	1.7	16
111	Endothelial function and hemorheological parameters modulate coronary blood flow in patients without significant coronary artery disease. Clinical Hemorheology and Microcirculation, 2012, 52, 255-266.	1.7	16
112	Chronic protection against ischemia and reperfusion-induced endothelial dysfunction during therapy with different organic nitrates. Clinical Research in Cardiology, 2012, 101, 453-459.	3.3	16
113	Both flow-mediated dilation andÂconstriction are associated withÂchanges inÂblood flow and shear stress:ÂTwoÂcomplementary perspectives onÂendothelial function. Clinical Hemorheology and Microcirculation, 2017, 64, 255-266.	1.7	16
114	Counterregulatory Responses: Sustained-Release Isosorbide-5-Mononitrate Versus Transdermal Nitroglycerin. Journal of Cardiovascular Pharmacology, 1996, 28, 631-638.	1.9	16
115	Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction. Journal of the American College of Cardiology, 1998, 32, 1680-1686.	2.8	15
116	Beta-Blockade Restores Muscle Sympathetic Rhythmicity in Human Heart Failure. Circulation Journal, 2011, 75, 1400-1408.	1.6	15
117	Impact of Nitrate Use on Survival in Acute Heart Failure: A Propensityâ€Matched Analysis. Journal of the American Heart Association, 2016, 5, .	3.7	15
118	Folic Acid Does Not Limit Endothelial Dysfunction Induced by Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2005, 46, 494-497.	1.9	14
119	Adverse effects of atrioventricular synchronous right ventricular pacing on left ventricular sympathetic activity, efficiency, and hemodynamic status. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2377-H2379.	3.2	13
120	Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study. European Journal of Echocardiography, 2007, 8, 275-283.	2.3	13
121	Long-Term Therapy With Organic Nitrates. Journal of the American College of Cardiology, 2004, 44, 632-634.	2.8	12
122	The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury. Clinical Hemorheology and Microcirculation, 2010, 45, 161-167.	1.7	12
123	Chronic pharmacological preconditioning against ischemia. Clinical Hemorheology and Microcirculation, 2011, 49, 287-293.	1.7	12
124	Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H153-H158.	3.2	12
125	Therapy with nitrates: increasing evidence of vascular toxicity**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology Journal of the American College of Cardiology. 2003, 42, 1835-1837.	2.8	11
126	Hemodynamic and neurochemical determinates of renal function in chronic heart failure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R167-R175.	1.8	11

#	Article	IF	CITATIONS
127	Dulaglutide and renal protection in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2018, 6, 588-590.	11.4	11
128	The role of vascular endothelium in nitroglycerinâ€mediated vasodilation. British Journal of Clinical Pharmacology, 2019, 85, 377-384.	2.4	10
129	Standard versus Low-Dose Transdermal Nitroglycerin: Differential Effects on the Development of Tolerance and Abnormalities of Endothelial Function. Journal of Cardiovascular Pharmacology, 2010, 56, 354-359.	1.9	9
130	Parameters of blood viscosity do not correlate with the extent of coronary and carotid atherosclerosis and with endothelial function in patients undergoing coronary angiography. Clinical Hemorheology and Microcirculation, 2012, 52, 245-254.	1.7	9
131	Clinical Validation of Non-Invasive Cardiac Output Monitoring in Healthy Pregnant Women. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 1008-1014.	0.7	9
132	Acute (but not chronic) smoking paradoxically protects the endothelium from ischemia and reperfusion: insight into the "smoking paradox― Clinical Research in Cardiology, 2013, 102, 387-389.	3.3	8
133	Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 313, R410-R417.	1.8	7
134	Increased extraction of endothelin-1 across the failing human heart. American Journal of Cardiology, 2001, 88, 180-182.	1.6	6
135	Effect of Diuretic Therapy on Exercise Capacity in Patients With Chronic Angina and Preserved Left Ventricular Function. Journal of Cardiovascular Pharmacology, 2007, 49, 275-279.	1.9	6
136	Cardiac resynchronization therapy after atrioventricular node ablation for rapid atrial fibrillation in a heart transplant recipient with late allograft dysfunction. Journal of Heart and Lung Transplantation, 2010, 29, 704-706.	0.6	6
137	Rosiglitazone Causes Endothelial Dysfunction in Humans. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 260-265.	2.0	6
138	Inverse relationship of subjective daytime sleepiness to mortality in heart failure patients with sleep apnoea. ESC Heart Failure, 2020, 7, 2448-2454.	3.1	6
139	Evaluation of a novel sutureless anastomotic connector: From endothelial function to mid-term clinical and angiographic follow-up. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 1555-1560.	0.8	5
140	Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease. Scientific Reports, 2020, 10, 565.	3.3	5
141	Platelet cyclic GMP responses to nitroglycerin. Cardiovascular Drugs and Therapy, 2000, 14, 419-425.	2.6	4
142	Continuous therapy with transdermal nitroglycerin does not affect biomarkers of vascular inflammation and injury in healthy volunteers. Canadian Journal of Physiology and Pharmacology, 2009, 87, 455-459.	1.4	4
143	Acetylcholine acutely modifies nitric oxide synthase function in the human coronary circulation. Experimental Physiology, 2010, 95, 1167-1176.	2.0	4
144	The impact of rosiglitazone on nitric oxide bioavailability and endothelial function. Clinical Hemorheology and Microcirculation, 2010, 45, 325-328.	1.7	4

#	Article	IF	CITATIONS
145	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
146	Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. Cardiology, 2015, 130, 69-81.	1.4	4
147	The Effect of Clopidogrel on the Response to Ischemia Reperfusion. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 368-373.	2.0	4
148	Daily low-dose folic acid supplementation does not prevent nitroglycerin-induced nitric oxide synthase dysfunction and tolerance: A human in vivo study. Canadian Journal of Cardiology, 2010, 26, 461-465.	1.7	3
149	Inhibition of sPLA2 and Endothelial Function: A Substudy of the SPIDER-PCI Trial. Canadian Journal of Cardiology, 2012, 28, 215-221.	1.7	3
150	Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 675-690.	1.4	3
151	Cyclooxygenase inhibition and rosuvastatin-induced vascular protection in the setting of ischemia–reperfusion: A human in vivo study. Vascular Pharmacology, 2015, 71, 159-165.	2.1	3
152	Therapeutic developments in the therapy of heart failure: lessons to be learned: Figure 1. European Heart Journal, 2015, 36, 1952-1954.	2.2	3
153	Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure. Journal of Cardiac Failure, 2021, , .	1.7	3
154	Deployment of Left Ventricular Lead from the Ipsilateral Side of Central Vein Obstruction. Journal of Interventional Cardiac Electrophysiology, 2005, 13, 47-50.	1.3	2
155	Role of Mitochondrial Aldehyde Dehydrogenase in Nitroglycerin-Mediated Vasodilation. Journal of Cardiovascular Pharmacology, 2019, 73, 359-364.	1.9	2
156	Nitrate tolerance: Current concepts concerning mechanisms and implications for therapy. ACC Current Journal Review, 1996, 5, 12-15.	0.1	1
157	Diuretic Therapy in Angina Pectoris: Effects on Nitrate Tolerance and Exercise Performance. American Journal of Cardiology, 1998, 81, 41A-43A.	1.6	1
158	Long-Acting Isosorbide Mononitrate. Drugs, 1999, 57, 100.	10.9	1
159	Renal handling of endothelin in patients with chronic heart failure. American Journal of Cardiology, 2005, 95, 532-534.	1.6	1
160	Identification of lateral cardiac veins for cardiac resynchronization therapy. Europace, 2006, 8, 506-507.	1.7	1
161	The acute administration of either amiloride or captopril does not prevent endothelial dysfunction induced by ischemia and reperfusion in the human forearm vasculature. Canadian Journal of Physiology and Pharmacology, 2010, 88, 996-1001.	1.4	1
162	Acute and Chronic Effects of Glyceryl Trinitrate Therapy on Insulin and Glucose Regulation in Humans. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 211-216.	2.0	1

#	Article	IF	CITATIONS
163	Resting and recruitable endothelial function – Evidence of two distinct circadian patterns. Clinical Hemorheology and Microcirculation, 2020, 74, 139-146.	1.7	1
164	Estimation of mitral valve area from regression analysis of the pressure gradient in mitral stenosis. American Journal of Cardiology, 1992, 69, 1050-1055.	1.6	0
165	Vasodilator and Nitrates. , 0, , 144-153.		Ο
166	Organic Nitrates: Exogenous Nitric Oxide Administration and Its Influence on the Vascular Endothelium. , 2007, , 1682-1689.		0
167	To the Editor:. Journal of Cardiovascular Electrophysiology, 2007, 18, E12-E12.	1.7	0
168	Evidence of a weak correlation between peripheral endothelial function measures and carotid intima-media thickness. Clinical Hemorheology and Microcirculation, 2012, 52, 235-243.	1.7	0
169	Medical Management of Chronic Stable Angina. , 2015, , 443-466.		Ο
170	Chronic congestive heart failure $\hat{a} \in $ " a new therapeutic choice. Cmaj, 2016, 188, 1137-1138.	2.0	0
171	Nitroglyzerininduzierte endotheliale Dysfunktion und Nitrattoleranz. , 2004, , 33-46.		Ο
172	Experimental Evaluation and Clinical Relevance of Tolerance to Nitrates. Developments in Cardiovascular Medicine, 1994, , 185-194.	0.1	0
173	Long-term Outcomes of Adults With Tricuspid Regurgitation Following Transcatheter Atrial Septal Defect Closure. Canadian Journal of Cardiology, 2022, 38, 330-337.	1.7	0